Lepodisiran

Lepodisiran
Clinical data
Other names	LY3819469; LY-3819469
Legal status
Legal status	Investigational;
Identifiers
CAS Number	2808361-18-2;
UNII	X4BE7S8PN9;

Lepodisiran (LY3819469) is a small interfering RNA that was developed to reduce lipoprotein(a) in people at risk of cardiovascular disease. It was developed by Eli Lilly and Company.

As of March 31 of 2025, company trials in phase 2 of randomized, double-blind, placebo-controlled study resulted in significant reduction of genetically inherited cardiovascular risk factors such as heart attacks, strokes, thrombosis, nearly 94% from baseline.

References

↑ Nissen, Steven E.; Linnebjerg, Helle; Shen, Xi; Wolski, Kathy; Ma, Xiaosu; Lim, Shufen; Michael, Laura F.; Ruotolo, Giacomo; Gribble, Grace; Navar, Ann Marie; Nicholls, Stephen J. (12 November 2023). "Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial". JAMA. 330 (21): 2075–2083. doi:10.1001/jama.2023.21835. ISSN 0098-7484. PMC 10641766. PMID 37952254.
↑ Boyanovsky, Boris B. (July 2023). "Lipoprotein(a) Lowering Medications: Another Step Forward in Atherosclerosis Management". Journal of Cardiovascular Pharmacology. 82 (1): 32–36. doi:10.1097/FJC.0000000000001438. PMID 37192439.
↑ "Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels". Eli Lilly and Company web page. March 30, 2025. Retrieved March 31, 2025.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by adding missing information.

[1] Nissen, Steven E.; Linnebjerg, Helle; Shen, Xi; Wolski, Kathy; Ma, Xiaosu; Lim, Shufen; Michael, Laura F.; Ruotolo, Giacomo; Gribble, Grace; Navar, Ann Marie; Nicholls, Stephen J. (12 November 2023). "Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial". JAMA. 330 (21): 2075–2083. doi:10.1001/jama.2023.21835. ISSN 0098-7484. PMC 10641766. PMID 37952254.

[2] Boyanovsky, Boris B. (July 2023). "Lipoprotein(a) Lowering Medications: Another Step Forward in Atherosclerosis Management". Journal of Cardiovascular Pharmacology. 82 (1): 32–36. doi:10.1097/FJC.0000000000001438. PMID 37192439.

[3] "Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels". Eli Lilly and Company web page. March 30, 2025. Retrieved March 31, 2025.